Table III.
Univariate and multivariate analysis of progression-free survival in the Chinese Glioma Genome Atlas microarray database.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Variables | HR (95% CI) | P-value | HR (95% CI) | P-value |
| CKAP2 Expression | 1.486 (1.171–1.884) | 0.001 | 2.003 (1.207–3.324) | 0.007 |
| Age | 1.021 (1.007–1.035) | 0.003 | 0.990 (0.966–1.015) | 0.430 |
| Gender | 1.114 (0.798–1.555) | 0.526 | ||
| Grade | 1.927 (1.307–2.842) | 0.001 | 0.662 (0.300–1.461) | 0.307 |
| KPS | 0.978 (0.965–0.992) | 0.002 | 0.971 (0.965–0.987) | <0.001 |
| IDH1 mutation | 0.546 (0.370–0.807) | 0.002 | 0.583 (0.276–1.232) | 0.158 |
| MGMT methylation | 0.617 (0.430–0.887) | 0.009 | 0.531 (0.270–1.044) | 0.067 |
| Chemotherapy | 0.448 (0.317–0.633) | <0.001 | 0.580 (0.323–1.042) | 0.068 |
| Radiotherapy | 0.600 (0.385–0.935) | 0.024 | 0.909 (0.437–1.891) | 0.799 |
CI, confidence interval; CKAP2, cytoskeletal-associated protein 2; HR, hazard ratio; IDH1, isocitrate dehydrogenase 1; KPS, Karnofsky Performance Status score; MGMT, O6-methylguanine DNA methyltransferase.